Is omeprazole (proton pump inhibitor) safe for a patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Omeprazole Safety in G6PD Deficiency

Omeprazole is safe to use in patients with G6PD deficiency—there is no evidence that proton pump inhibitors cause hemolysis in this population.

Medications Definitively Contraindicated in G6PD Deficiency

Only seven medications have solid evidence for causing hemolysis and should be avoided 1:

  • Dapsone 2, 3, 1
  • Methylthioninium chloride (methylene blue) 2, 3, 1
  • Primaquine 2, 3, 1
  • Rasburicase 2, 1
  • Nitrofurantoin 1
  • Phenazopyridine 1
  • Tolonium chloride (toluidine blue) 1

Why Omeprazole Is Safe

Omeprazole and other proton pump inhibitors are not listed among medications that cause hemolysis in G6PD deficiency 1. The comprehensive evidence-based review examining all medications and G6PD deficiency found no evidence contraindicating the use of proton pump inhibitors in normal therapeutic doses 1.

A large real-world study of 31,962 G6PD-deficient patients identified only 71 cases (0.2%) of major hemolysis requiring hospitalization over 12 years, with 71.8% caused by fava beans, 8.5% by infections, and only 4.2% possibly medication-related (nitrofurantoin, phenazopyridine, and an unspecified "pain killer")—notably, no proton pump inhibitors were implicated 4.

Common Pitfall to Avoid

Many medications have been wrongly cited as causing hemolysis because they were administered during infection-related hemolytic episodes 1. Over time, this has led to unnecessarily restrictive medication lists that cause patient distress and limit therapeutic options 1.

Clinical Approach When Prescribing Any Medication

When starting any new medication in a G6PD-deficient patient, monitor for signs of hemolysis including 2:

  • Jaundice
  • Dark urine (hemoglobinuria)
  • Fatigue
  • Back or abdominal pain
  • Anemia

The Mediterranean variant (Gdmed) causes more severe, potentially life-threatening hemolysis compared to the African variant (GdA-), which typically produces milder, self-limited reactions 3, 5.

References

Guideline

Management of G6PD Deficiency in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Medications Contraindicated in G6PD Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

G6PD Deficiency Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.